The U.S. Food and Drug Administration said a panel of experts would discuss a marketing application from Eli Lilly & Co on a new targeted lung cancer treatment. The FDA said the panel would review data that showed improved overall survival rate in lung cancer patients treated with a combination of Lilly’s experimental drug, necitumumab, […]

A drug to increase sexual desire in women showed a statistically significant benefit, according to a preliminary review by the U.S. Food and Drug Administration, but the agency raised concerns about an increased risk of fainting and falling blood pressure. “The fundamental question is whether these observed placebo-corrected treatment effects outweigh the risks associated with […]

The genetically altered, cancer-killing T-cells known as CARTs showed dramatic results in non-Hodgkin lymphoma as the two leading players, the Swiss drug giant Novartis and the Seattle upstart Juno Therapeutics, pushed forward with new clinical trials. The new results are to be presented at the annual meeting of the American Society of Clinical Oncology by […]

Former chief scientific officer for Shire Pharmaceuticals and Relmada Therapeutics also headed R&D for Adolor and Stem Cells, Inc.; a trained psychiatrist and CNS specialist, Dr. Salinas arrives as Turing readies clinical trial programs NEW YORK (June 1, 2015) – Turing Pharmaceuticals AG announced that life sciences executive and medical researcher Eliseo Oreste Salinas, MD, MSc,  […]

The National Cancer Institute in July will start enrolling patients in a clinical trial seeking to match the underlying genetic defect driving a person’s tumor with one or more of 20 approved or experimental drugs targeting that gene.  The announcement, made at the American Society for Clinical Oncology meeting on Monday, is meant to use […]

The head of Merck KGaA’s healthcare division said she expected its cancer drug avelumab, jointly developed with Pfizer, to be among the first two or three to market in a field of immunotherapy pharmaceuticals that harness the power of the immune system in a range of cancer types. Other developers of immunotherapy drugs have won […]

Those with a vested interest in the development of new cancer therapies have been spoiled once again by data presented at the ongoing annual meeting of the American Society of Clinical Oncology (ASCO). For the third year in a row, immuno-oncology treatments – particularly the PD-1/PD-L1 inhibitors – have dominated headlines. With ASCO providing the […]

June 1, 2015By Riley McDermid, BioSpace.com Breaking News Sr. Editor Boulder, Colo.-based Clovis Oncology (CLVS) has become an even more attractive takeover target after it presented data Saturday at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago that showed its ovarian cancer drug shrunk tumors in 82 percent of the […]

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced results from CheckMate -017, a Phase III, open-label, randomized study evaluating Opdivo (n=135) versus docetaxel (n=137) in previously treated patients with advanced squamous non-small cell lung cancer. At one year, Opdivo demonstrated an overall survival rate of 42% versus 24% for docetaxel, with a median overall survival […]

Adding an experimental Celldex Therapeutics Inc vaccine that enlists the immune system to fight cancer to standard therapy helped patients with the deadliest type of brain cancer live longer, according to data from a midstage trial presented on Sunday. In the trial of 73 patients whose glioblastoma multiforme (GBM) had recurred after prior therapy, 30 […]